(original)

PATENT CLAIMS

1. Use of glucocorticoid receptor antagonists with a relative binding affinity for the glucocorticoid receptor bond between 85% and 155% of that of dexamethasone and with a relative binding affinity for the progesterone receptor bond between 1% and 11% of that of progesterone or with a 14-fold to 150-fold dissociation between the two receptor types, for the production of a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

(original)

2. 11β-Substituted steroids as glucocorticoid receptor antagonists of general formula (I)



wherein

R_1 is a methyl, methoxy or ethoxy group and

R_2 is a tert.butyl group, sec.propyl alcohol or sec. propyl ether or a substituted benzene ring.

(original)

3. 11β-Substituted steroids according to Claim 2,
namely
21-tert.butyl-17-hydroxy-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
methyl-4-{17-hydroxy-11β-[3-(methoxy)phenyl]-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)}benzoate,
3-{17-hydroxy-11β-[3-(methoxy)phenyl]-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)}benzaldehyde,
4-{17-hydroxy-11β-[3-(methoxy)phenyl]-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)}

phenylacetate,
17-hydroxy-11β-[3-(methoxy)phenyl)]-21-(4-pyrrolyl)phenyl-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-hydroxyphenyl)-11β-[3-(methoxy)phenyl)]-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesylphenyl)-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
21-tert.butyl-17-hydroxy-11β-(3-ethoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
21-(4-tert.butylphenyl)-17-hydroxy-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
ethyl(E)-3-[17-hydroxy-11β-(3-methoxyphenyl)-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)} isocrotonate,
21-(3,5-difluorophenyl)-17-hydroxy-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
21-(2-trifluorophenyl)-17-hydroxy-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
21-(3,5-dimethylphenyl)-17-hydroxy-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
4-{17-hydroxy-11β-[3-(methoxy)phenyl]-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)} phenylsulfamate,
17-hydroxy-21-(1-hydroxy-1-methylethyl)-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
3-(17-hydroxy-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-11β -yl)benzaldehyde,
(E)-3-[17-hydroxy-11β-(3-methoxyphenyl)-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl)benzaldoxime,
17-hydroxy-21-(1-methoxy-1-methylethyl)-11β-(3-methoxyphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesylphenyl)-11β-(3-methylphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one,
17-hydroxy-21-(4-mesyloxyphenyl)-11β-(3-methylphenyl)-19-nor-17α-pregna-4,9-dien-20-yn-3-one, and
4-{17-hydroxy-11β-[3-methylphenyl)]-3-keto-19-nor-17α-pregna-4,9-dien-20-yn-21-yl} phenylaminoacetate.

(currently amended)

4. Use of 11β-substituted steroids as glucocorticoid receptor antagonists according to ~~Claims 2 and 3~~ Claim 2 for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

(currently amended)

Claim 1

5. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 4,~~ characterized in that

the administration occurs orally, subcutaneously, sublingually, in the form of an inhalator or as a plaster, ointment or gel.

(currently amended)

6. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 5~~ Claim 1 for producing a drug, characterized in that the daily dose to be administered is from 0.01 mg to 100 mg per body weight [sic].